Table 1.
Baseline characteristics of patients in the study (N=73).
| Characteristics | Value | |
| Age (years), mean (SD) | 68.42 (10.25) | |
| Male, n (%) | 38 (52) | |
| Medical history, n (%) |
|
|
|
|
Hypertension | 37 (51) |
|
|
Diabetes | 16 (22) |
|
|
Congestive heart failure | 15 (21) |
|
|
Previous stroke/TIAa | 10 (14) |
|
|
Renal dysfunction | 6 (8) |
|
|
Liver dysfunction | 4 (6) |
|
|
Peripheral vascular disease | 4 (6) |
| Type of atrial fibrillation, n (%) |
|
|
|
|
Paroxysmal | 35 (48) |
|
|
Persistent | 28 (38) |
|
|
Permanent | 10 (14) |
| Atrial fibrillation treatment, n (%) |
|
|
|
|
Beta-blocker | 34 (47) |
|
|
Pharmacologic cardioversion | 15 (21) |
|
|
Anticoagulant therapyb | 28 (38) |
|
|
Atrial fibrillation ablation | 8 (11) |
|
|
LAAOc | 1 (1) |
| Anthropometric data, n (%) |
|
|
|
|
BMI (kg/m2) | 23.15 (5.49) |
|
|
Overweightd | 21 (29) |
|
|
Current drinker | 36 (49) |
|
|
Current smoker | 28 (38) |
| Daily caregiver, n (%) |
|
|
|
|
Spouse or children | 62 (85) |
|
|
Relative | 8 (11) |
|
|
Others | 3 (4) |
| CHA2DS2-VASce score, mean (SD) | 2.89 (1.71) | |
| HAS-BLEDf score, mean (SD) | 2.32 (1.13) | |
aTIA: transient ischemic attack.
bAnticoagulant therapy denotes receiving vitamin K antagonist or nonvitamin K antagonist oral anticoagulant.
cLAAO: left atrial appendage occlusion.
dOverweight denotes BMI≥25 kg/m2.
eCHA2DS2-VASc: congestive heart failure, hypertension, age≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65-74, female gender.
fHAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly.